Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Apr;67(4):801–805. doi: 10.1038/bjc.1993.146

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

R P A'Hern 1, I E Smith 1, S R Ebbs 1
PMCID: PMC1968345  PMID: 8471439

Abstract

The value of the inclusion of doxorubicin hydrochloride (dox) in Cooper type regimens in advanced breast cancer was assessed by performing an overview employing summary statistics derived from published papers of randomised clinical trials comparing Cooper type regimens that contain dox with regimens in which dox was replaced by one or more compounds. Trials were selected which published data on survival, time to treatment failure and response rate. This study suggests that dox confers advantages on all of these endpoints and that the size of such benefits needs to be taken into account when deciding whether to use dox.

Full text

PDF
801

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A'Hern R. P., Ebbs S. R., Baum M. B. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer. 1988 Jun;57(6):615–618. doi: 10.1038/bjc.1988.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aisner J., Weinberg V., Perloff M., Weiss R., Perry M., Korzun A., Ginsberg S., Holland J. F. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. J Clin Oncol. 1987 Oct;5(10):1523–1533. doi: 10.1200/JCO.1987.5.10.1523. [DOI] [PubMed] [Google Scholar]
  3. Belanger D., Moore M., Tannock I. How American oncologists treat breast cancer: an assessment of the influence of clinical trials. J Clin Oncol. 1991 Jan;9(1):7–16. doi: 10.1200/JCO.1991.9.1.7. [DOI] [PubMed] [Google Scholar]
  4. Berlin J. A., Laird N. M., Sacks H. S., Chalmers T. C. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989 Feb;8(2):141–151. doi: 10.1002/sim.4780080202. [DOI] [PubMed] [Google Scholar]
  5. Bull J. M., Tormey D. C., Li S. H., Carbone P. P., Falkson G., Blom J., Perlin E., Simon R. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer. 1978 May;41(5):1649–1657. doi: 10.1002/1097-0142(197805)41:5<1649::aid-cncr2820410501>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  6. Cummings F. J., Gelman R., Horton J. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol. 1985 Jul;3(7):932–940. doi: 10.1200/JCO.1985.3.7.932. [DOI] [PubMed] [Google Scholar]
  7. Freedman L. S. The size of clinical trials in cancer research--what are the current needs? Medical Research Council Cancer Therapy Committee. Br J Cancer. 1989 Mar;59(3):396–400. doi: 10.1038/bjc.1989.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. MANTEL N., HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed] [Google Scholar]
  9. Smalley R. V., Lefante J., Bartolucci A., Carpenter J., Vogel C., Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat. 1983;3(2):209–220. doi: 10.1007/BF01803563. [DOI] [PubMed] [Google Scholar]
  10. Thompson S. G., Pocock S. J. Can meta-analyses be trusted? Lancet. 1991 Nov 2;338(8775):1127–1130. doi: 10.1016/0140-6736(91)91975-z. [DOI] [PubMed] [Google Scholar]
  11. Tormey D. C., Weinberg V. E., Leone L. A., Glidewell O. J., Perloff M., Kennedy B. J., Cortes E., Silver R. T., Weiss R. B., Aisner J. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. Am J Clin Oncol. 1984 Jun;7(3):231–239. doi: 10.1097/00000421-198406000-00007. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES